Xilio TherapeuticsXLO
13F holders, Q2 2025 (June 30)35holders
5new positions
5sold out
1famous investor
$0.68avg. 13F price*
At the end of Q2 2025, 35 institutions reported holding Xilio Therapeutics Inc. (XLO) in their 13F filings, unchanged from Q1 2025. 5 opened new positions and 5 sold out. The largest holders were Gilead Sciences, Inc. ($6.2M), Bain Capital Life Sciences Investors, LLC ($3.1M) and Merck & Co., Inc. ($1.0M). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Xilio Therapeutics Inc.
- CUSIP
- 98422T100
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 5 | $1.1M |
| Exits | 5 | $111K |
All 13F filers, Q1 2025 → Q2 2025: 2,030,293 shares bought and 763,236 shares sold, net +1,267,057 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 35 holders
| Gilead Sciences, Inc. | 0.48% | No change | 9,105,451 | $6.2M |
| Bain Capital Life Sciences Investors, LLC | 0.39% | No change | 4,566,817 | $3.1M |
| Merck & Co., Inc. | 0.47% | No change | 1,483,758 | $1.0M |
| Takeda Pharmaceutical Co. Ltd. | 5.13% | No change | 1,475,121 | $1.0M |
| Morgan Stanley | 0.00% | Add +25.0% | 1,444,326 | $982K |
| Ghisallo Capital Management LLC | 0.02% | New | 1,333,000 | $906K |
| Vanguard Group Inc. | 0.00% | Add +1.4% | 1,151,023 | $783K |
| AJU IB Investment Co., Ltd. | 0.49% | No change | 667,742 | $454K |
| FMR LLC | 0.00% | Reduce -42.1% | 511,820 | $348K |
| Geode Capital Management, LLC | 0.00% | Reduce -2.5% | 369,660 | $251K |
| Trustees of Columbia University in the City of New York | 0.02% | No change | 249,635 | $170K |
| UBS Group AG | 0.00% | Add +47.1% | 239,969 | $163K |
| Squarepoint Ops LLC | 0.00% | New | 235,456 | $160K |
| Balyasny Asset Management L.P. | 0.00% | Reduce -21.8% | 198,859 | $135K |
| Renaissance Technologies | 0.00% | Reduce -7.6% | 164,200 | $112K |
| Avantax Planning Partners, Inc. | 0.00% | Reduce -5.4% | 142,338 | $97K |
| Two Sigma Investments, LP | 0.00% | Reduce -7.2% | 78,032 | $53K |
| Northern Trust Corp. | 0.00% | No change | 66,609 | $45K |
| Bridgeway Capital Management, LLC | 0.00% | Reduce -21.1% | 56,081 | $38K |
| State Street Corp. | 0.00% | No change | 43,390 | $30K |
| XTX Topco Ltd | 0.00% | New | 34,721 | $24K |
| LPL Financial LLC | 0.00% | New | 31,000 | $21K |
| SevenBridge Financial Group, LLC | 0.00% | Reduce -45.6% | 25,000 | $18K |
| Aptus Capital Advisors, LLC | 0.00% | Reduce -45.6% | 25,000 | $17K |
| Mariner, LLC | 0.00% | No change | 25,000 | $17K |
| Raymond James Financial Inc. | 0.00% | Reduce -44.8% | 18,761 | $13K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 15,412 | $10K |
| Dunhill Financial, LLC | 0.00% | No change | 10,274 | $7K |
| Investors Asset Management of Georgia Inc. /Ga/ | 0.00% | No change | 10,000 | $7K |
| Pinnacle Financial Group, LLC / IL | 0.00% | No change | 10,000 | $7K |
| Federation des caisses Desjardins du Quebec | 0.00% | No change | 3,300 | $2K |
| BlackRock, Inc. | 0.00% | Reduce -97.3% | 2,037 | $1K |
| Key Financial Inc | 0.00% | No change | 830 | $564 |
| Bank of America Corp. | 0.00% | Add +14.1% | 331 | $225 |
| Private Wealth Management Group, LLC | 0.00% | No change | 310 | $211 |
"% of holder's portfolio" is XLO's weight in each manager's 13F, not the share of Xilio Therapeutics Inc. the manager owns.